Immunohistochemical and ultrastructural review of six cases previously diagnosed as null cell PitNETs.

Electron microscopy Null cell pituitary neuroendocrine tumor Transcription factors Ultrastructure

Journal

Brain tumor pathology
ISSN: 1861-387X
Titre abrégé: Brain Tumor Pathol
Pays: Japan
ID NLM: 9716507

Informations de publication

Date de publication:
Jul 2023
Historique:
received: 04 03 2023
accepted: 07 04 2023
medline: 3 7 2023
pubmed: 19 4 2023
entrez: 18 04 2023
Statut: ppublish

Résumé

Pituitary neuroendocrine tumors (PitNETs) lacking lineage affiliation are termed "null cell" PitNETs (NCTs). NCTs are characterized as being immunonegative for pituitary hormones as well as transcription factors. We analyzed the ultrastructure and immunohistochemistry of six hormone-negative and transcription factor (TPIT, PIT1, SF1)-negative PitNETs, with less than 1% immunoreactive cells. Histologically, three cases presented a perivascular pattern and pseudorosettes; the other three showed a solid pattern with oncocytic changes. Electron microscopic examination revealed poorly differentiated tumor cells with sparsely scattered secretory granules and intracellular organelles in all null cell tumors when compared with hormone-positive PitNETs. Two cases harbored a honeycomb Golgi (HG) structure, and three oncocytic tumors showed mitochondrial accumulation. The two HG cases were immunopositive for newly obtained TPIT (CL6251) and showed some adrenocorticotropic hormone-positive cells, while the remaining four were diffusely immunopositive for GATA3, with two SF1-positive cases identified in subsequent immunostaining. Thus, these six cases may be classified as two sparsely granulated corticotroph PitNETs, two gonadotroph PitNETs with SF1 re-staining, and two likely gonadotroph PitNETs with GATA3 immunostaining. No "true NCT" was detected among 1071 PitNETs, demonstrating the importance of precise diagnosis following the most recent criteria to improve therapeutic success.

Identifiants

pubmed: 37072666
doi: 10.1007/s10014-023-00462-9
pii: 10.1007/s10014-023-00462-9
doi:

Substances chimiques

Transcription Factors 0
Hormones 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

158-162

Subventions

Organisme : MEXT KAKENHI
ID : 19185472

Informations de copyright

© 2023. The Author(s), under exclusive licence to The Japan Society of Brain Tumor Pathology.

Références

Kovacs K, Horvath E, Ryan N et al (1980) Null cell adenoma of the human pituitary. Virchows Archiv A Pathol Anat Histol 387:165–174
doi: 10.1007/BF00430697
Lloyd RV, Osamura RY, Klöppel G (eds) (2017) Pituitary adenoma. In WHO classification of tumours of endocrine organs, 4th edn. IARC, Lyon, pp 12–40
Nishioka H, Inoshita N, Mete O et al (2015) The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr Pathol 26:349–355
doi: 10.1007/s12022-015-9398-z pubmed: 26481628
Asa SL, Mete O, Perry A et al (2022) Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr Pathol 33:6–26
doi: 10.1007/s12022-022-09703-7 pubmed: 35291028
Almeida JP, Stephens CC, Eschbacher JM et al (2019) Clinical, pathologic, and imaging characteristics of pituitary null cell adenomas as defined according to the 2017 World Health Organization criteria: a case series from two pituitary centers. Pituitary 22(5):514–519
doi: 10.1007/s11102-019-00981-9 pubmed: 31401793
Kovacs K, Horvath E (1986) Tumors of the pituitary gland. Atlas of Tumor Pathology, Fascicle 21. 2nd Series. AFIP, Washington
Sano T, Mader R, Asa SL et al (2003) “Honeycomb Golgi” in pituitary adenomas: not a marker of gonadotroph adenomas. Endocr Pathol 14:363–368
doi: 10.1385/EP:14:4:363 pubmed: 14739492
Horvath E, Kovacs K (1984) Gonadotroph adenomas of the human pituitary: sex-related fine-structural dichotomy. A histologic, immunocytochemical, and electron-microscopic study of 30 tumors. Am J Pathol 117:429–440
pubmed: 6095670 pmcid: 1900593
Niveiro M, Aranda FI, Payá A et al (2004) Oncocytic transformation in pituitary adenomas: immunohistochemical analyses of 65 cases. Arch Pathol Lab Med 128:776–780
doi: 10.5858/2004-128-776-OTIPAI pubmed: 15214824
Sjöstedt E, Bollerslev J, Mulder J et al (2017) A specific antibody to detect transcription factor T-Pit: a reliable marker of corticotroph cell differentiation and a tool to improve the classification of pituitary neuroendocrine tumours. Acta Neuropathol 134:675–677
doi: 10.1007/s00401-017-1768-9 pubmed: 28823042
Sano T, Yamada S (1994) Histologic and immunohistochemical study of clinically non-functioning pituitary adenomas: special reference to gonadotropin-positive adenomas. Pathol Int 44:697–703
doi: 10.1111/j.1440-1827.1994.tb02949.x pubmed: 7804432
Al-Brahim NY, Asa SL (2006) My approach to pathology of the pituitary gland. J Clin Pathol 59:1245–1253
doi: 10.1136/jcp.2005.031187 pubmed: 17142570 pmcid: 1860551
Trouillas J, Jaffrain-Rea ML, Vasiljevic A et al (2020) How to classify the pituitary neuroendocrine tumors (PitNET)s in 2020. Cancers (Basel) 12:514
doi: 10.3390/cancers12020514 pubmed: 32098443
Dottermusch M, Schüller U, Hagel C et al (2023) Unveiling the identities of null cell tumours: epigenomics corroborate subtle histological cues in pituitary neuroendocrine tumour/adenoma classification. Neuropathol Appl Neurobiol 49:e12870
doi: 10.1111/nan.12870 pubmed: 36527335

Auteurs

Naoko Inoshita (N)

Department of Pathology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, 105-8470, Japan. inonao3939@gmail.com.
Department of Pathology, Moriyama Memorial Hospital, 4-3-1 Kitakasai, Edogawa-Ku, Tokyo, 134-0081, Japan. inonao3939@gmail.com.
Okinaka Memorial Institute for Medical Research, 2-2-2 Toranomon, Minato-Ku, Tokyo, 105-8470, Japan. inonao3939@gmail.com.

Toyoki Yoshimoto (T)

Department of Pathology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, 105-8470, Japan.

Yutaka Takazawa (Y)

Department of Pathology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, 105-8470, Japan.

Noriaki Fukuhara (N)

Okinaka Memorial Institute for Medical Research, 2-2-2 Toranomon, Minato-Ku, Tokyo, 105-8470, Japan.
Department of Hypothalamic and Pituitary Surgery, Toranomon Hospital, Tokyo, 105-8470, Japan.

Mitsuo Okada (M)

Okinaka Memorial Institute for Medical Research, 2-2-2 Toranomon, Minato-Ku, Tokyo, 105-8470, Japan.
Department of Hypothalamic and Pituitary Surgery, Toranomon Hospital, Tokyo, 105-8470, Japan.

Hiroshi Nishioka (H)

Okinaka Memorial Institute for Medical Research, 2-2-2 Toranomon, Minato-Ku, Tokyo, 105-8470, Japan.
Department of Hypothalamic and Pituitary Surgery, Toranomon Hospital, Tokyo, 105-8470, Japan.

Shozo Yamada (S)

Department of Hypothalamic and Pituitary Surgery, Toranomon Hospital, Tokyo, 105-8470, Japan.
Department of Hypothalamic and Pituitary Surgery, Memorial Hospital, 4-3-1 Kitakasai, Edogawa-Ku, Tokyo, 134-0081, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH